-
Views
-
Cite
Cite
Ensifentrine, American Journal of Health-System Pharmacy, Volume 81, Issue 22, 15 November 2024, Pages 1084–1085, https://doi.org/10.1093/ajhp/zxae248
- Share Icon Share
Extract
Brand: Ohtuvayre®
AHFS Classification: 48:34
Introduction
Ensifentrine is an inhibitor of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4).
Uses
Ensifentrine has the following uses:
...
Dosage and Administration
General
Ensifentrine is available in the following dosage form(s) and strength(s): Inhalation suspension: 3 mg/2.5 mL aqueous suspension in unit-dose ampules.
Dosage
It isessentialthat the manufacturer’s labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:
Adults
Dosage and Administration
...
Cautions
Contraindications
...
Warnings and Precautions
Acute Episodes of Bronchospasm
Ensifentrine should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. Ensifentrine has not been studied in the relief of acute symptoms and extra doses should not be used for that purpose. The safety and effectiveness of ensifentrine for relief of acute symptoms have not been established. Acute symptoms should be treated with an inhaled, short-acting bronchodilator.
Comments